Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis.

Cipriani S, Chen X, Schwarzschild MA.

Biomark Med. 2010 Oct;4(5):701-12. doi: 10.2217/bmm.10.94. Review.

2.

Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease.

Facheris MF, Hicks AA, Minelli C, Hagenah JM, Kostic V, Campbell S, Hayward C, Volpato CB, Pattaro C, Vitart V, Wright A, Campbell H, Klein C, Pramstaller PP.

J Mol Neurosci. 2011 Mar;43(3):246-50. doi: 10.1007/s12031-010-9409-y. Epub 2010 Jun 30.

PMID:
20589538
3.

Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study.

Schwingenschuh P, Ruge D, Edwards MJ, Terranova C, Katschnig P, Carrillo F, Silveira-Moriyama L, Schneider SA, K├Ągi G, Palomar FJ, Talelli P, Dickson J, Lees AJ, Quinn N, Mir P, Rothwell JC, Bhatia KP.

Mov Disord. 2010 Apr 15;25(5):560-9. doi: 10.1002/mds.23019.

4.

Imaging for early differential diagnosis of parkinsonism.

Antonini A.

Lancet Neurol. 2010 Feb;9(2):130-1. doi: 10.1016/S1474-4422(09)70360-6. Epub 2010 Jan 8. No abstract available.

PMID:
20061184
5.

Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease.

Ponsen MM, Stoffers D, Wolters ECh, Booij J, Berendse HW.

J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):396-9. doi: 10.1136/jnnp.2009.183715. Epub 2009 Dec 3.

PMID:
19965851
6.

Urate as a predictor of the rate of clinical decline in Parkinson disease.

Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA; Parkinson Study Group DATATOP Investigators.

Arch Neurol. 2009 Dec;66(12):1460-8. doi: 10.1001/archneurol.2009.247. Epub .

7.

Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study.

Chen H, Mosley TH, Alonso A, Huang X.

Am J Epidemiol. 2009 May 1;169(9):1064-9. doi: 10.1093/aje/kwp033. Epub 2009 Mar 18.

8.

Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs).

Silveira-Moriyama L, Schwingenschuh P, O'Donnell A, Schneider SA, Mir P, Carrillo F, Terranova C, Petrie A, Grosset DG, Quinn NP, Bhatia KP, Lees AJ.

J Neurol Neurosurg Psychiatry. 2009 Jul;80(7):744-8. doi: 10.1136/jnnp.2009.172825. Epub 2009 Mar 9.

PMID:
19276101
9.

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.

Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A; Parkinson Study Group PRECEPT Investigators, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J.

Arch Neurol. 2008 Jun;65(6):716-23. doi: 10.1001/archneur.2008.65.6.nct70003. Epub 2008 Apr 14.

10.

Diet, urate, and Parkinson's disease risk in men.

Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A.

Am J Epidemiol. 2008 Apr 1;167(7):831-8. doi: 10.1093/aje/kwm385. Epub 2008 Mar 7.

11.

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.

Parkinson Study Group PRECEPT Investigators.

Neurology. 2007 Oct 9;69(15):1480-90. Epub 2007 Sep 19.

PMID:
17881719
12.

Plasma urate and risk of Parkinson's disease.

Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A.

Am J Epidemiol. 2007 Sep 1;166(5):561-7. Epub 2007 Jun 20.

13.

Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging.

Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG.

Nucl Med Commun. 2006 Dec;27(12):933-7.

PMID:
17088677
14.

Serum uric acid levels and the risk of Parkinson disease.

de Lau LM, Koudstaal PJ, Hofman A, Breteler MM.

Ann Neurol. 2005 Nov;58(5):797-800.

PMID:
16240356
15.

Mitochondria take center stage in aging and neurodegeneration.

Beal MF.

Ann Neurol. 2005 Oct;58(4):495-505. Review.

PMID:
16178023
16.

Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.

Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE; Parkinson Study Group.

Neurology. 2005 Jan 11;64(1):87-93.

PMID:
15642909
17.

Levodopa and the progression of Parkinson's disease.

Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group.

N Engl J Med. 2004 Dec 9;351(24):2498-508.

18.

(123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis.

Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K.

Arch Neurol. 2004 Aug;61(8):1224-9.

PMID:
15313838
19.

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ; REAL-PET Study Group.

Ann Neurol. 2003 Jul;54(1):93-101.

PMID:
12838524
20.

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.

Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ.

Brain. 2002 Apr;125(Pt 4):861-70.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk